Ascending afferent regulation of rat midbrain dopamine neurons

doi:10.1016/0361-9230(93)90121-Q

Brain Research Bulletin

Volume 31, Issue 5, 1993, Pages 539-546

https://doi.org/10.1016/0361-9230(93)90121-Q Get rights and content

Abstract

Standard, extracellular single-unit recording techniques were used to examine the electrophysiological and pharmacological responsiveness of midbrain dopamine (DA) neurons to selected, ascending afferent inputs. Sciatic nerve stimulation-induced inhibition of nigrostriatal DA (NSDA) neurons was blocked by both PCPA (5-HT synthesis inhibitor) and 5,7-DHT (5-HT neurotoxin), suggesting mediation by a serotonergic (5-HT) system. Direct stimulation of the dorsal raphe (which utilizes 5-HT as a neurotransmitter and inhibits slowly firing NSDA neurons) inhibited all mesoaccumbens DA (MADA) neurons tested. Paradoxically, DPAT, a 5-HT_1a agonist which inhibits 5-HT cell firing, enhanced sciatic nerve stimulation-induced inhibition of NSDA neurons. MADA neurons were not inhibited by sciatic nerve stimulation and, therefore, could not be tested in this paradigm. In contrast to the dorsal raphe, electrical stimulation of the pedunculopontine tegmental nucleus preferentially excited slowly firing NSDA and MADA neurons. Thus, both excitatory and inhibitory ascending afferents influence the activity of midbrain DA neurons, and intact 5-HT systems are necessary for sciatic nerve stimulation to alter DA cell activity. However, the role that 5-HT plays in mediating peripheral sensory input remains unclear.

References (59)

B.S. Bunney
Antipsychotic drug effects on the electrical activity of dopaminergic neurons
Trends Neurosci.
(1984)
L.A. Chiodo
Dopamine-containing neurons in the mammalian central nervous system: Electrophysiology and pharmacology
Neurosci. Biobehav. Rev.
(1988)
L.A. Chiodo et al.
Sensory stimuli alter the discharge rate of dopamine (DA) neurons: Evidence for two functional types of DA cells in the substantia nigra
Brain Res.
(1980)
L.A. Chiodo et al.
Reciprocal influences of activating and immobilizing stimuli on the activity of nigrostriatal dopamine neurons
Brain Res.
(1979)
P.B.S. Clarke et al.
Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: Neuroanatomical and electrophysiological evidence
Neuroscience
(1987)
J. Feger et al.
Peripheral excitatory input to substantia nigra
Exp. Neurol.
(1978)
E. Gould et al.
Cholinergic projections to the substantia nigra from the pedunculopontine and laterodorsal tegmental nuclei
Neuroscience
(1989)
A.A. Grace et al.
Peripheral and striatal influences on nigral dopamine cells: Mediation by reticulata neurons
Brain Res. Bull.
(1980)
P.G. Guyenet et al.
Antidromic identification of dopaminergic and other output neurons of the substantia nigra
Brain Res.
(1978)
D.W. Hommer et al.
Effects of sensory stimuli on the activity of dopaminergic neurons: Involvement of non-dopaminergic nigral neurons and striato-nigral pathways
Life Sci.
(1980)

A. Jackson et al.

Nucleus tegmenti pedunculopontinus: Efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase

Neuroscience

(1983)

M.D. Kelland et al.

Pedunculopontine tegmental nucleus-induced inhibition of muscle activity in the rat

Behav. Brain Res.

(1989)

J. Lipski

Antidromic activation of neurones as an analytical tool in the study of the central nervous system

J. Neurosci. Methods

(1981)

J.T. Lum et al.

Electrophysiological evidence that spiperone is an antagonist of 5-HT_1a receptors in the dorsal raphe nucleus

Eur. J. Pharmacol.

(1988)

J. Mantz et al.

Effect of noxious tail pinch on the discharge rate of mesocortical and mesolimbic dopamine neurons: Selective activation of the mesocortical system

Brain Res.

(1989)

M. Marcinkiewicz et al.

Autoradiographic evidence for the heterogeneity of 5-HT₁ sites in the rat brain

Brain Res.

(1984)

K. Niijima et al.

Activation of mesencephalic dopamine neurons by chemical stimulation of the nucleus tegmenti pedunculopontinus pars compacta

Brain Res.

(1988)

A. Pazos et al.

Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors

Brain Res.

(1985)

E. Scarnati et al.

Pedunculopontine evoked excitation of substantia nigra neurons in the rat

Brain Res.

(1984)

C.M. Sinton et al.

Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT₁ receptor

Eur. J. Pharmacol.

(1988)

D. Wirtshafter et al.

Evidence that serotonergic projections to the substantia nigra in the rat arise in the dorsal, but not the median, raphe nucleus

Neurosci. Lett

(1987)

G.K. Aghajanian et al.

Dopaminergic and nondopaminergic neurons of the substantia nigra: Differential responses to putative transmitters

S. Benkirane et al.

A functional response to D₁ dopamine receptor stimulation in the central nervous system: Inhibition of the release of [³H]-serotonin from the rat substantia nigra

Naunyn Schmiedebergs Arch. Pharmacol.

(1987)

P. Blier et al.

Modification of 5-HT neuron properties by sustained administration of the 5-HT_1a agonist gepirone: Electrophysiological studies in the rat brain

Synapse

(1987)

P. Blier et al.

Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT_1a receptors without altering 5-HT autoreceptor sensitivity: An electrophysiological study in the rat brain

Synapse

(1987)

B.S. Bunney et al.

Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity

J. Pharmacol. Exp. Ther.

(1973)

J. Church et al.

N-Methyl-D-aspartate (NMDA) antagonism is central to the actions of ketamine and other phencyclidine receptor ligands

D. Clark et al.

Review: D1 dopamine receptor—The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

Synapse

(1987)

G. Corssen et al.

Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581

Anesth. Analg.

(1966)

Cited by (66)

Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence
2021, Progress in Brain Research
The interaction between serotonin (5-HT) and dopamine (DA) in the central nervous system (CNS) plays an important role in the adaptive properties of living animals to their environment. These are two modulatory, divergent systems shaping and regulating in a widespread manner the activity of neurobiological networks and their interaction. The concept of one interaction linking these two systems is rather elusive when looking at the mechanisms triggered by these two systems across the CNS. The great variety of their interacting mechanisms is in part due to the diversity of their neuronal origin, the density of their fibers in a given CNS region, the distinct expression of their numerous receptors in the CNS, the heterogeneity of their intracellular signaling pathway that depend on the cellular type expressing their receptors, and the state of activity of neurobiological networks, conditioning the outcome of their mutual influences. Thus, originally conceptualized as inhibition of 5-HT on DA neuron activity and DA neurotransmission, this interaction is nowadays considered as a multifaceted, mutual influence of these two systems in the regulation of CNS functions. These new ways of understanding this interaction are of utmost importance to envision the consequences of their dysfunctions underlined in several CNS diseases. It is also essential to conceive the mechanism of action of psychotropic drugs directly acting on their function including antipsychotic, antidepressant, antiparkinsonian, and drug of abuse together with the development of therapeutic strategies of Alzheimer's diseases, epilepsy, obsessional compulsive disorders. The 5-HT/DA interaction has a long history from the serendipitous discovery of antidepressants and antipsychotics to the future, rationalized treatments of CNS disorders.
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications
2017, Progress in Neurobiology
Citation Excerpt :
The inhibitory response of SNc and VTA DA neurons triggered by DRN stimulation was eliminated by 5-HT depletion with para-chlorophenylalanine (pCPA) or 5,7-dihydroxytryptamine (5,7-DHT), but the percentage of DA neurons initially excited was maintained (Fibiger and Miller, 1977; Gervais and Rouillard, 2000). Therefore, 5-HT seems to selectively inhibit a subset of DA neurons including the SNc slow firing cells and the VTA neurons projecting to the NAc (Kelland et al., 1993). This is a direct, phasic rather than tonic, inhibitory 5-HT monosynaptic input from the DRN (Dray et al., 1976; Fibiger and Miller, 1977; Gervais and Rouillard, 2000).
Since their discovery in the mammalian brain, it has been apparent that serotonin (5-HT) and dopamine (DA) interactions play a key role in normal and abnormal behavior. Therefore, disclosure of this interaction could reveal important insights into the pathogenesis of various neuropsychiatric diseases including schizophrenia, depression and drug addiction or neurological conditions such as Parkinson’s disease and Tourette’s syndrome. Unfortunately, this interaction remains difficult to study for many reasons, including the rich and widespread innervations of 5-HT and DA in the brain, the plethora of 5-HT receptors and the release of co-transmitters by 5-HT and DA neurons. The purpose of this review is to present electrophysiological and biochemical data showing that endogenous 5-HT and pharmacological 5-HT ligands modify the mesencephalic DA systems’ activity. 5-HT receptors may control DA neuron activity in a state-dependent and region-dependent manner. 5-HT controls the activity of DA neurons in a phasic and excitatory manner, except for the control exerted by 5-HT_2C receptors which appears to also be tonically and/or constitutively inhibitory. The functional interaction between the two monoamines will also be discussed in view of the mechanism of action of antidepressants, antipsychotics, anti-Parkinsonians and drugs of abuse.
New therapeutic opportunities for 5-HT<inf>2C</inf> receptor ligands in neuropsychiatric disorders
2016, Pharmacology and Therapeutics
Citation Excerpt :
These inhibitory effects could involve 5-HT2CRs but the demonstration is missing. Lesion of 5-HT neurons or depletion of 5-HT does not modify DA neuron firing rate (Kelland et al., 1990, 1993; Prisco et al., 1994; Prisco & Esposito, 1995; Gervais & Rouillard, 2000; Guiard et al., 2008) although it is sometimes associated with subtle changes of the discharge profile of DA neurons (Prisco et al., 1994; Guiard et al., 2008). The tonic control exerted by 5-HT2CRs on DA neuron firing rate is consequently not clear and could be related to the nature and the selectivity of the 5-HT2C antagonists/inverse agonists used to unmask the continuous regulations (see below) or the contribution of other 5-HTRs.
The 5-HT_2C receptor (R) displays a widespread distribution in the CNS and is involved in the action of 5-HT in all brain areas. Knowledge of its functional role in the CNS pathophysiology has been impaired for many years due to the lack of drugs capable of discriminating among 5-HT₂R subtypes, and to a lesser extent to the 5-HT_1B, 5-HT₅, 5-HT₆ and 5-HT₇Rs. The situation has changed since the mid-90s due to the increased availability of new and selective synthesized compounds, the creation of 5-HT_2C knock out mice, and the progress made in molecular biology. Many pharmacological classes of drugs including antipsychotics, antidepressants and anxiolytics display affinities toward 5-HT_2CRs and new 5-HT_2C ligands have been developed for various neuropsychiatric disorders. The 5-HT_2CR is presumed to mediate tonic/constitutive and phasic controls on the activity of different central neurobiological networks. Preclinical data illustrate this complexity to a point that pharmaceutical companies developed either agonists or antagonists for the same disease.
In order to better comprehend this complexity, this review will briefly describe the molecular pharmacology of 5-HT_2CRs, as well as their cellular impacts in general, before addressing its central distribution in the mammalian brain. Thereafter, we review the preclinical efficacy of 5-HT_2C ligands in numerous behavioral tests modeling human diseases, highlighting the multiple and competing actions of the 5-HT_2CRs in neurobiological networks and monoaminergic systems. Notably, we will focus this evidence in the context of the physiopathology of psychiatric and neurological disorders including Parkinson's disease, levodopa-induced dyskinesia, and epilepsy.
Sensory regulation of dopaminergic cell activity: Phenomenology, circuitry and function
2014, Neuroscience
Dopaminergic neurons in a range of species are responsive to sensory stimuli. In the anesthetized preparation, responses to non-noxious and noxious sensory stimuli are usually tonic in nature, although long-duration changes in activity have been reported in the awake preparation as well. However, in the awake preparation, short-latency, phasic changes in activity are most common. These phasic responses can occur to unconditioned aversive and non-aversive stimuli, as well as to the stimuli which predict them. In both the anesthetized and awake preparations, not all dopaminergic neurons are responsive to sensory stimuli, however responsive neurons tend to respond to more than a single stimulus modality. Evidence suggests that short-latency sensory information is provided to dopaminergic neurons by relatively primitive subcortical structures – including the midbrain superior colliculus for vision and the mesopontine parabrachial nucleus for pain and possibly gustation. Although short-latency visual information is provided to dopaminergic neurons by the relatively primitive colliculus, dopaminergic neurons can discriminate between complex visual stimuli, an apparent paradox which can be resolved by the recently discovered route of information flow through to dopaminergic neurons from the cerebral cortex, via a relay in the colliculus. Given that projections from the cortex to the colliculus are extensive, such a relay potentially allows the activity of dopaminergic neurons to report the results of complex stimulus processing from widespread areas of the cortex. Furthermore, dopaminergic neurons could acquire their ability to reflect stimulus value by virtue of reward-related modification of sensory processing in the cortex. At the forebrain level, sensory-related changes in the tonic activity of dopaminergic neurons may regulate the impact of the cortex on forebrain structures such as the nucleus accumbens. In contrast, the short latency of the phasic responses to sensory stimuli in dopaminergic neurons, coupled with the activation of these neurons by non-rewarding stimuli, suggests that phasic responses of dopaminergic neurons may provide a signal to the forebrain which indicates that a salient event has occurred (and possibly an estimate of how salient that event is). A stimulus-related salience signal could be used by downstream systems to reinforce behavioral choices.
Mechanisms underlying sleep-wake disturbances in alcoholism: Focus on the cholinergic pedunculopontine tegmentum
2014, Behavioural Brain Research
Citation Excerpt :
Interestingly, research in drug addiction has demonstrated that the primary mechanism for relapse (i.e. reinstatement of drug-seeking behavior, an animal model of relapse) involves activation of glutamatergic cells in the medial prefrontal cortex (mPFC), which then activates dopaminergic (DAergic) projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) [173–179]. Additionally, a number of anatomical, behavioral, physiological, and pharmacological studies have provided evidence to demonstrate that the CCC-PPT receives excitatory input from the mPFC [179–182] and sends cholinergic afferent projections to the VTA [183–186], where they synapse on DAergic neurons that then project to the NAc [180,181,187–195], resulting in the release of DA in the NAc [183,196–198]. Furthermore, administration of a partial nicotinic receptor agonist varenicline has been shown in both preclinical and clinical trials to reduce ethanol consumption [199–202].
Sleep–wake (S–W) disturbances are frequently associated with alcohol use disorders (AUD), occurring during periods of active drinking, withdrawal, and abstinence. These S–W disturbances can persist after months or even years of abstinence, suggesting that chronic alcohol consumption may have enduring negative effects on both homeostatic and circadian sleep processes. It is now generally accepted that S–W disturbances in alcohol-dependent individuals are a significant cause of relapse in drinking. Although significant progress has been made in identifying the socio-economic burden and health risks of alcohol addiction, the underlying neurobiological mechanisms that lead to S–W disorders in AUD are poorly understood. Marked progress has been made in understanding the basic neurobiological mechanisms of how different sleep stages are normally regulated. This review article in seeking to explain the neurobiological mechanisms underlying S–W disturbances associated with AUD, describes an evidence-based, easily testable, novel hypothesis that chronic alcohol consumption induces neuroadaptive changes in the cholinergic cell compartment of the pedunculopontine tegmentum (CCC-PPT). These changes include increases in N-methyl-d-aspartate (NMDA) and kainate receptor sensitivity and a decrease in gamma-aminobutyric acid (GABA_B)-receptor sensitivity in the CCC-PPT. Together these changes are the primary pathophysiological mechanisms that underlie S–W disturbances in AUD. This review is targeted for both basic neuroscientists in alcohol addiction research and clinicians who are in search of new and more effective therapeutic interventions to treat and/or eliminate sleep disorders associated with AUD.
Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors
2010, International Review of Neurobiology
Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and l-dopa. When combined with decarboxylase inhibitor l-dopa is the most efficacious treatment for Parkinson’s disease. Bioavailability and efficacy of l-dopa treatment can be enhanced greatly by the use of COMT inhibitors. This has been the driving force for development of new selective and potent COMT inhibitors. The success in COMT inhibitor development has generated a tremendous scientific interest in the role of COMT in health and disease. COMT inhibitors have also helped to clarify the reaction mechanism of COMT, increased interest in its structural biology, and physicochemical properties in order to develop even better COMT inhibitors. New techniques, especially the transgenic mice, have revealed further new aspects about the role of COMT in periphery as well as in the brain.

View all citing articles on Scopus

View full text

ArticleAscending afferent regulation of rat midbrain dopamine neurons

Abstract

Trends Neurosci.

Neurosci. Biobehav. Rev.

Brain Res.

Brain Res.

Neuroscience

Exp. Neurol.

Neuroscience

Brain Res. Bull.

Brain Res.

Life Sci.

Neuroscience

Behav. Brain Res.

J. Neurosci. Methods

Eur. J. Pharmacol.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Eur. J. Pharmacol.

Neurosci. Lett

Dopaminergic and nondopaminergic neurons of the substantia nigra: Differential responses to putative transmitters

A functional response to D1 dopamine receptor stimulation in the central nervous system: Inhibition of the release of [3H]-serotonin from the rat substantia nigra

Naunyn Schmiedebergs Arch. Pharmacol.

Modification of 5-HT neuron properties by sustained administration of the 5-HT1a agonist gepirone: Electrophysiological studies in the rat brain

Synapse

Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1a receptors without altering 5-HT autoreceptor sensitivity: An electrophysiological study in the rat brain

Synapse

Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity

J. Pharmacol. Exp. Ther.

N-Methyl-D-aspartate (NMDA) antagonism is central to the actions of ketamine and other phencyclidine receptor ligands

Review: D1 dopamine receptor—The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

Synapse

Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581

Anesth. Analg.

Article
Ascending afferent regulation of rat midbrain dopamine neurons

A functional response to D₁ dopamine receptor stimulation in the central nervous system: Inhibition of the release of [³H]-serotonin from the rat substantia nigra

Modification of 5-HT neuron properties by sustained administration of the 5-HT_1a agonist gepirone: Electrophysiological studies in the rat brain

Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT_1a receptors without altering 5-HT autoreceptor sensitivity: An electrophysiological study in the rat brain